Symbolbild · KI-generiert
GH Research PLC
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
GH Research is a clinical-stage biopharmaceutical company focused on developing 5-MeO-DMT-based therapies for psychiatric disorders. Its primary focus is the treatment of treatment-resistant depression using inhaled and injectable formulations of the compound.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| GH Research PLC | GHRS | NASDAQ | 1,92 Mrd. USD |
| Aurinia Pharmaceuticals Inc | AUPH | NASDAQ | 1,93 Mrd. USD |
| HUTCHMED (China) Limited | HCM | NASDAQ | 1,94 Mrd. USD |
| Tyra Biosciences, Inc. | TYRA | NASDAQ | 1,90 Mrd. USD |
| ADMA Biologics Inc | ADMA | NASDAQ | 1,97 Mrd. USD |
| UroGen Pharma Ltd. | URGN | NASDAQ | 1,86 Mrd. USD |
| SELLAS Life Sciences Group, Inc. | SLS | NASDAQ | 1,86 Mrd. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.